HJTA
HJTA is a selective, pH/GSH dual-responsive Fluorescent probe and anticancer agent. HJTA selectively undergoes an enzymatic reaction with GSTπ. HJTA induces Apoptosis and Autophagy by regulating the expression of apoptotic and autophagic proteins. HJTA exhibits pH- and GSH-dual-responsive fluorescence in tumor cells. HJTA selectively illuminates tumor tissues, enabling precise in situ visualization of colon tumors. HJTA exerts anticancer effects against colon cancer. HJTA can be used for colon cancer research.
For research use only. We do not sell to patients.
- CAS No.: 2442502-32-9
- Formula: C28H27N3O6
- Molecular Weight:501.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
1.57 μM
Compound: HJTA
|
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
|
[PMID: 32787089] |
HJTA potently inhibits the proliferation of HT29, HepG2 and 9L-2 cancer cells[1].
HJTA (0.4-2.5 μM; 72 h) induces apoptosis in colon cancer HT29 cells in a dose-dependent manner, and its mechanism of action involves upregulating Bax, downregulating Bcl-2, and activating caspase-3 and PARP[1].
HJTA (0.4-2.5 μM) induces autophagy in colon cancer cells HT29 in a dose-dependent manner, which is characterized by increased levels of LC3-II and Beclin-1, decreased level of p62, and elevated LC3-II/LC3-I ratio[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HT29 human colon cancer cells
-
Concentration:0.4-2.5 μM
-
Incubation Time:72 h
-
Result:Induced apoptotic cell percentages of 36.8% (1.0 μM), and 52.3% (2.5 μM).
Increased pro-apoptotic Bax levels dose-dependently.
Decreased anti-apoptotic Bcl-2 levels dose-dependently.
Increased levels of cleaved caspase-3 and cleaved PARP dose-dependently.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 5−6 weeks old)[1]
-
Dosage:20 mg/kg; 40 mg/kg
-
Administration:i.p.; daily; 21 days
-
Result:Reduced mean tumor weight by 67.7% (40 mg/kg group) relative to the control group.
Significantly reduced tumor volume growth over the 21-day period relative to the control group, with the 40 mg/kg dose showing greater tumor growth inhibition than the 20 mg/kg dose.
Showed no significant changes in body weight between HJTA-treated groups and the control group.
-
Animal Model:ICR (female)[1]
-
Dosage:240.0 mg/kg; 300.0 mg/kg; 375.0 mg/kg; 468.8 mg/kg; 585.9 mg/kg
-
Administration:i.p.; single dose
-
Result:Achieved 100% survival over 14 days with no abnormalities in body weight, eating, drinking, or activity in the 240.0 mg/kg and 300.0 mg/kg groups.
Achieved 80% survival with 2 deaths occurring by day 4 in the 375.0 mg/kg group.
Achieved 40% survival with 6 deaths occurring by day 4 in the 468.8 mg/kg group.
Achieved 10% survival with 9 deaths occurring by day 14 in the 585.9 mg/kg group.
Had a calculated median lethal dose (LD50) of 475 mg/kg.
Chemical Information
-
CAS No. 2442502-32-9
-
Molecular Weight 501.53
-
Formula C28H27N3O6
-
SMILES
O=C1C(COC(NC2=CC3=C(NC4=CC=CC=C43)C(C5=CC(OC)=C(C(OC)=C5)OC)=N2)=O)=CCCC1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HJTA Related Classifications
HY-D3211 Related Classifications
Powered by Bioz